We are live on
!
Find out more
PVI
Pura Vida Investments Portfolio holdings
AUM
$14.9M
1-Year Est. Return
38.76%
This Fund
S&P 500
This Quarter
Est. Return
-9.64%
1 Year Est. Return
+38.76%
3 Year Est. Return
+26.8%
5 Year Est. Return
+25.03%
10 Year Est. Return
+1,723.84%
AUM
$585M
AUM Growth
-$73.1M
(-11%)
Cap. Flow
+$1.63M
Cap. Flow
% of AUM
0.28%
Top 10 Holdings %
Top 10 Hldgs %
31.26%
Holding
141
New
43
Increased
25
Reduced
14
Closed
51
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
GRFS
Grifois
GRFS
|
+$10.6M |
| 2 |
XENT
Intersect ENT, Inc
XENT
|
+$6.54M |
| 3 |
Regeneron Pharmaceuticals
REGN
|
+$5.92M |
| 4 |
ALXN
Alexion Pharmaceuticals
ALXN
|
+$5.92M |
| 5 |
Establishment Labs
ESTA
|
+$5.5M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Boston Scientific
BSX
|
+$10.1M |
| 2 |
Danaher
DHR
|
+$7.15M |
| 3 |
ARQL
Arqule Inc
ARQL
|
+$6.98M |
| 4 |
Guardant Health
GH
|
+$6.04M |
| 5 |
AbbVie
ABBV
|
+$5.82M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 39.74% |
| 2 | Industrials | 1.15% |
| 3 | Consumer Staples | 0.71% |
| 4 | Materials | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
76
Arvinas
ARVN
$588M
| $1.38M | 0.24% |
+64,209
| New | +$1.58M |
|
|
STML
77
DELISTED
Stemline Therapeutics, Inc.
STML
| $1.38M | 0.24% |
132,422
-21,176
| -14% | -$277K |
|
78
KALA BIO
KALA
$16.3M
| $1.27M | 0.22% |
133
+13
| +11% | +$158K |
|
79
Zymeworks
ZYME
$1.73B
| $1.24M | 0.21% |
+50,000
| New | +$1.25M |
|
|
INOV
80
DELISTED
Inovalon Holdings, Inc. Class A Common Stock
INOV
| $1.23M | 0.21% |
+75,000
| New | +$1.2M |
|
81
Axsome Therapeutics
AXSM
$11.1B
| $1.18M | 0.2% |
58,519
+50,719
| +650% | +$1.3M |
|
82
Coherus Oncology
CHRS
$187M
| $1.01M | 0.17% |
50,000
-59,196
| -54% | -$1.18M |
|
83
Natera
NTRA
$45.1B
| $984K | 0.17% |
+30,000
| New | +$887K |
|
|
ITCI
84
DELISTED
Intra-Cellular Therapies Inc.
ITCI
| $815K | 0.14% |
+109,130
| New | +$1.05M |
|
85
Ardelyx
ARDX
$982M
| $658K | 0.11% |
+140,085
| New | +$487K |
|
|
ENDP
86
CALL
DELISTED
Endo International plc
ENDP
| $642K | 0.11% |
+200,000
| New | +$645K |
|
87
uniQure
QURE
$3.12B
| $590K | 0.1% |
+15,000
| New | +$865K |
|
|
ADVM
88
DELISTED
Adverum Biotechnologies
ADVM
| $545K | 0.09% |
+10,000
| New | +$1.13M |
|
|
AVDL
89
DELISTED
Avadel Pharmaceuticals
AVDL
| $505K | 0.09% |
+121,435
| New | +$304K |
|
|
RNTX
90
Rein Therapeutics
RNTX
$69.9M
| $91K | 0.02% |
+6,777
| New | +$93.8K |
|
|
91
AbbVie
ABBV
$442B
| – | – |
-79,980
| Closed | -$5.82M |
|
92
Adaptive Biotechnologies
ADPT
$4.04B
| – | – |
-35,000
| Closed | -$1.69M |
|
|
AMRN
93
Amarin Corp
AMRN
$296M
| – | – |
-11,760
| Closed | -$4.56M |
|
94
Artivion
AORT
$1.38B
| – | – |
-70,000
| Closed | -$2.1M |
|
95
CALL
Accuray
ARAY
$34.6M
| – | – |
-800,000
| Closed | -$3.1M |
|
|
AVNS
96
DELISTED
Avanos Medical
AVNS
| – | – |
-85,000
| Closed | -$3.71M |
|
97
Avantor
AVTR
$9.31B
| – | – |
-250,000
| Closed | -$4.77M |
|
98
PUT
Axogen
AXGN
$2.61B
| – | – |
-200,000
| Closed | -$3.96M |
|
99
Azenta
AZTA
$1.54B
| – | – |
-95,000
| Closed | -$3.68M |
|
100
CALL
Becton Dickinson
BDX
$49.4B
| – | – |
-51,250
| Closed | -$12.6M |
|
Similar funds
BCA
RC
DOFI
SCI
LPC
GBCP
SCTC
M
Pura Vida Investments's Q3 2019 Portfolio in Review
As of Q3 2019, Pura Vida Investments held 141 positions worth $585M, down 11% from $658M the previous quarter. Its ten largest holdings account for 31% of the portfolio.
Pura Vida Investments's Q3 2019 filing shows 43 new, 25 increased, 14 reduced and 51 closed positions. Its largest new stake was Grifois: 496,201 shares worth $9.94M. The largest sale was Boston Scientific, an estimated $10.1M.
By sector, the portfolio is most concentrated in Healthcare at 40% of assets, down from 45% a quarter earlier, followed by Industrials and Consumer Staples.
- Pura Vida Investments's largest Q3 2019 buy was Grifois: 496,201 shares worth $9.94M.
- Pura Vida Investments added most to Intersect ENT, Inc in Q3 2019, an estimated $6.54M increase.
- Pura Vida Investments's biggest Q3 2019 reduction was Zimmer Biomet, cutting an estimated $5.66M.
- Pura Vida Investments fully exited Boston Scientific in Q3 2019, selling an estimated $10.1M.
- Pura Vida Investments's ten largest holdings make up 31% of its $585M portfolio in Q3 2019.
- Pura Vida Investments opened 43 new positions and closed 51 in Q3 2019.
- Pura Vida Investments's portfolio value fell 11% quarter-over-quarter to $585M.
Based on Pura Vida Investments's 13F filing for Q3 2019, filed 14 Nov 2019.